Skip to content

Effect of letrozole on ovarian hyper stimulation

Comparison the efficacy of Letrozole-gonadotropins and clomiphene citrate-gonadotropins in Ovarian hyper stimulation of infertile women undergoing intra uterine insemination procedure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201106236868N1
Enrollment
80
Registered
2011-07-20
Start date
2010-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Female Infertility

Interventions

Intervention 1: first group: letrozole-gonadotropin patients in group letrozole (group A) will receive 5 mg letrozole for five days from day 3 of the menstrual cycle. Intervention 2: Second group: clo
Treatment - Drugs
first group: letrozole-gonadotropin patients in group letrozole (group A) will receive 5 mg letrozole for five days from day 3 of the menstrual cycle
Second group: clomiphen citrate - gonadotropin In the CC-gonadotropin group (Group B) clomiphene citrate 100 mg will be given for 5 days starting from day 3 of menstrual cycle.

Sponsors

Tabriz University of Medical Mciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: unovulation, poly cystic ovary syndrome Exclusion criteria: ifertility with the tubal cause ( occlusion of one or both tubes), infertility with sever male cause (less than 10 milion motile sperm), intrauterine masses ( myoma and polyp), uterine endometrioma, age over 35 year of women

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
First follicle generation. Timepoint: one dy another 7-9 days after period. Method of measurement: vaginl ultrasonography.

Secondary

MeasureTime frame
Pregnancy. Timepoint: 18 days after IUI. Method of measurement: by BHCG.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr mahzad mehrzad sadaghiani

Tabriz University of Medical Sciences

sadaghainim@tbzmed.ac.ir+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026